Next Article in Journal
Kanamycin and Ofloxacin Activate the Intrinsic Resistance to Multiple Antibiotics in Mycobacterium smegmatis
Next Article in Special Issue
Exploring the Potent Roles of an Internally Translated Truncated Connexin-43 Isoform
Previous Article in Journal
Diminishing the Pathogenesis of the Food-Borne Pathogen Serratia marcescens by Low Doses of Sodium Citrate
Previous Article in Special Issue
Discovery of GJC1 (Cx45) as a New Gene Underlying Congenital Heart Disease and Arrhythmias
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biology
Volume 12
Issue 4
10.3390/biology12040505
biology-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Molecular Mechanisms and Clinical Phenotypes of GJB2 Missense Variants

by
Lu Mao
1,
Yueqiang Wang
2,
Lei An
3,
Beiping Zeng
1,
Yanyan Wang
4,
Dmitrij Frishman
5,
Mengli Liu
1,
Yanyu Chen
1,
Wenxue Tang
4 and
Hongen Xu
1,4,*
1
Precision Medicine Center, Academy of Medical Science, Zhengzhou University, Zhengzhou 450052, China
2
Basecare Medical Device Co., Ltd., Suzhou 215000, China
3
Translational Medicine Center, Huaihe Hospital of Henan University, Kaifeng 475000, China
4
The Research and Application Center of Precision Medicine, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014, China
5
Wissenschaftszentrum Weihenstephan, Technische Universitaet Muenchen, Am Staudengarten 2, 85354 Freising, Germany
*
Author to whom correspondence should be addressed.
Biology 2023, 12(4), 505; https://doi.org/10.3390/biology12040505
Submission received: 18 November 2022 / Revised: 19 January 2023 / Accepted: 20 January 2023 / Published: 27 March 2023
(This article belongs to the Collection Gap Junctions and Connexins in Physiology, Pharmacology and Disease)
Browse Figures
Review Reports Versions Notes

Abstract

:

Simple Summary

Hearing loss is the most common sensory impairment in humans. Globally, GJB2 is the most common responsible gene, with missense variants being the most frequent variant type. Pathogenic missense variants in the GJB2 gene cause isolated hearing loss and hearing loss combined with skin diseases. However, the mechanism by which different missense variants cause different hearing loss phenotypes is unknown. We have summarized 84 functionally studied missense variants and reviewed the clinical phenotypes and the molecular mechanisms that affected connexon and gap junction functions. We have also compiled a comprehensive dataset of GJB2 missense variants from public databases and published literature and found that over 2/3 of the GJB2 missense variants are currently classified as variants of uncertain significance. With the development of cutting-edge deep mutational scanning technology, we predict that the molecular mechanisms by which all missense variants of GJB2 lead to different clinical phenotypes will be elucidated. These gained insights will facilitate the use of genetic testing in the prevention and control of hearing loss.

Abstract

The GJB2 gene is the most common gene responsible for hearing loss (HL) worldwide, and missense variants are the most abundant type. GJB2 pathogenic missense variants cause nonsyndromic HL (autosomal recessive and dominant) and syndromic HL combined with skin diseases. However, the mechanism by which these different missense variants cause the different phenotypes is unknown. Over 2/3 of the GJB2 missense variants have yet to be functionally studied and are currently classified as variants of uncertain significance (VUS). Based on these functionally determined missense variants, we reviewed the clinical phenotypes and investigated the molecular mechanisms that affected hemichannel and gap junction functions, including connexin biosynthesis, trafficking, oligomerization into connexons, permeability, and interactions between other coexpressed connexins. We predict that all possible GJB2 missense variants will be described in the future by deep mutational scanning technology and optimizing computational models. Therefore, the mechanisms by which different missense variants cause different phenotypes will be fully elucidated.

1. Introduction

Hearing loss (HL) is a common sensory defect in humans. According to the World Health Organization, in 2021, more than 5% of the world’s population (~430 million) had debilitating HL and required rehabilitation [1]. There are an estimated 1–3 HL patients in China for every 1000 newborns [2,3]. HL affects speech acquisition and cognitive, social, and emotional development. Although various environmental factors can cause HL, most congenital deafness (50–60%) is attributable to genetic factors [4]. In general, hereditary HL is categorized as syndromic (30%) or nonsyndromic (70%), depending on the presence or absence of other clinical features. Currently, more than 120 genes are known to be causative genes for hereditary deafness (https://hereditaryhearingloss.org/, accessed on 18 November 2022), mainly encoding functional proteins involved in the development and function of the auditory system, such as transcription factors, structural proteins, ion channels, and gap junction proteins [5].
The GJB2 gene is most commonly responsible for HL worldwide, accounting for up to 50% of nonsyndromic deafness. Different pathogenic variants predominate in different countries [6]. GJB2 pathogenic variants include nonsense, small insertions or deletions, missense, and splicing variants. By 2021, the Human Gene Mutation Database (http://www.hgmd.cf.ac.uk/ac/index.php, accessed on 31 December 2021) had compiled 457 GJB2 pathogenic variants, of which 303 (66.3%) were missense that covered ~70% (156/226) of the amino acid sites. Pathogenic missense variants in GJB2 are a major cause of nonsyndromic HL and syndromic HL associated with skin disorders [7]. However, approximately 100 GJB2 missense variants have definitive functions, and two-thirds have yet to be studied functionally. A systematic study of the effects on the protein functions of all of the GJB2 missense variants will provide a basis for understanding the molecular mechanisms by which the GJB2 missense variants lead to different clinical deafness phenotypes. Here we review the protein’s structural, positional, and functional changes and the clinical phenotypes caused by different missense variants in the GJB2 gene. We mainly focus on those that have been functionally studied.

2. Structure and Function of the GJB2 Gene

The GJB2 gene is located on chromosome 13q12. It contains two exons and one intron. The coding region is located in exon 2 and encodes a protein containing 226 amino acids, also known as Connexin 26 (Cx26). Cx26 molecules share a common topology with other members of the connexin family, which includes two extracellular domains (E1, and E2), three intracellular domains (NT, CL, and CT), and four transmembrane domains (M1, M2, M3, and M4) (Figure 1A) [8]. Connexons (also known as hemichannels) are homomeric or heteromeric, depending on whether the same or different connexins are utilized as building blocks. They are trafficked to the cell surface in vesicles to connect the cytoplasm and the extracellular environment [9]. Two identical or different connexons can form a complete homotypic, heterotypic, or heteromeric gap junction (GJ) channel by docking through the extracellular domain (Figure 1B) [8,10,11,12]. GJs mediate intercellular communication by allowing the diffusion of ions, metabolites, and small signaling molecules, which are crucial for cell growth, differentiation, and development [13,14]. The human Cx26 gene is highly conserved and ablation of Cx26 in mice is embryonic lethal, indicating the essential functional roles of Cx26 in maintaining hemostasis of the human body [15]. Currently, there are several hypotheses for the pathogenic mechanism of Cx26-related hearing loss caused by defective hemichannel or gap junction channel function: potassium recycling disruption, adenosine-triphosphate-calcium signaling propagation disruption, and energy supply dysfunction [16,17,18].

3. Effect of GJB2 Missense Variants on the Cx26 Protein

The life cycle of Cx26 includes protein translation, post-translational modifications, degradation of Cx26 molecules, assembly into hemichannel, intracellular trafficking of connexons to the plasma membrane, docking of the connexons from neighboring cells to form GJs, and interactions between other coexpressed connexins (Figure 2) [19,20,21]. The most common variant type for the GJB2 gene is frameshift, such as c.35delG in Europeans and c.235delC in East Asians. These truncating variants usually lead to Cx26 lacking one or several of the transmembrane segments and intervening loops, which hampers Cx26 folding and oligomerization, resulting in retention at the endoplasmic reticulum (ER) and ultimately causing a total loss of function [22].
As the most abundant variant type for the GJB2 gene, different missense variants can disrupt intercellular communication by affecting all of the Cx26 life cycle stages [20,22]. A recent review categorized GJB2 missense variants based on whether the affected residues were involved in maintaining the structural stability or impaired the function of Cx26 [22]. In the present review, we summarize missense variants based on the functional consequence revealed by in vitro functional studies: impaired trafficking of connexons to the plasma membrane, reduced hemichannel or GJ functions, cell death caused by elevated hemichannel activity, and dominant or trans-dominant effects on wildtype Cx26 or other coexpressed connexins [23,24]. To date, roughly 100 GJB2 missense variants with clear functions have been identified, and the pathogenesis of most missense variants remains unclear [22,25]. Therefore, it is crucial to investigate the effects of missense variants on protein functions and the molecular mechanisms by which different missense variants lead to different clinical phenotypes.
Cx26 is transcribed in the nucleus and trafficked to the endoplasmic reticulum (ER) for translation into proteins. Hydrolases in lysosomes are mainly used to degrade mistranslated proteins. Wildtype connexins oligomerize in the ER/Golgi. Microtubules assist hemichannels to traffic to the cell surface to allow communication between the cellular cytoplasm and the extracellular space. Hemichannels dock with the hemichannels of adjacent cells, forming gap junctions to traffic ions and other low-molecular-weight components between cells. ER: Endoplasmic reticulum

4. Association between GJB2 Missense Variants with Clinical Phenotypes

Pathogenic variants in GJB2 can cause nonsyndromic autosomal recessive or dominant HL [26] and syndromic HL associated with skin disease [7], including palmoplantar keratoderma (PPK) with deafness [27], Vohwinkel syndrome [28], keratitis-ichthyosis-deafness (KID) syndrome [29], hystrix-like ichthyosis with deafness (HID) [30], and Bart–Pumphrey syndrome (BPS) [31]. The skin abnormalities in these syndromic forms include follicular hyperkeratosis, palmoplantar stippled keratoderma, knuckle pads, leukonychia, and spotty hyperpigmentation [32]. The mechanisms leading to the different clinical phenotypes still need to be fully characterized. We have summarized these missense variants where there are functional studies and have grouped them into four general scenarios (Figure 3). These in vitro functional studies were performed using model cell lines, including transfected HeLa, HEK-293, NEB1 cells or the cochlear-relevant HEI-OC1 cells from mice, and the paired Xenopus oocytes expression system. The models were used to investigate the cellular localization and membrane trafficking of the mutant proteins, their ability to form functional gap junctions, and their relationship with the Cx26 wild type and other expressed connexins caused by missense variants [20].

4.1. Nonsyndromic HL Caused by GJB2 Missense Variants

4.1.1. Nonsyndromic HL Caused by GJB2 Recessive Missense Variants

Recessive variants in the GJB2 gene only cause nonsyndromic HL. To date, 50 autosomal recessive variants have been functionally studied. Some (16/50) have defective trafficking, some (7/50) have impaired trafficking, and others (24/50) have normal trafficking to the plasma membrane but have functionally impaired hemichannels and GJ channels (Table 1, see notes for the difference between defective trafficking and impaired trafficking). The recessive GJB2 missense variants that have been functionally studied are distributed in all structural domains except the C-terminal domain. There are more variants in the N-terminal (6/50), EC1 (6/50), TM2 (8/50), CL (7/50), EC2 (7/50), and TM4 (11/50) structural domains, and only a small number of variants in the EC1 (3/50) and TM3 (2/50) structural domains.
Some missense variants largely accumulate in the endoplasmic reticulum (ER) or Golgi around the nucleus. They cannot translocate properly to the cell membrane to form GJ channels and affect protein function. In vitro evaluation of the G12V variant showed that the mutant protein was entirely intracellular, clustered in large perinuclear vesicles, and showed no evidence of membrane targeting [33]. The mutant protein of T86R did not form GJs because the mutant protein was retained in the cells [34]. However, when the mutant was coexpressed with wildtype Cx26, there was normal ionic and biochemical coupling, consistent with the recessive nature. Variants that share this pathogenic mechanism include M1V, R32C, R32H, I35S, W77R, S85Y, P173R, R184P, K188R, S199F, G200R, I203K, L205P, and T208P (Table 1).
Table
Table 1. Molecular mechanisms and phenotypes of nonsyndromic hearing loss variants.
Table 1. Molecular mechanisms and phenotypes of nonsyndromic hearing loss variants.
VariantsLocationsInheritance PatternsTrafficking HemichannelsGap Junction ChannelClinical PhenotypeReferences
M1VNTARdefect//severe/profound[35,36]
T8MNTARnormal/impairedsevere/profound[37,38,39]
L10PNTARnormalimpairedimpairedprofound[39,40]
G12VNTARdefect//mild/moderate[33,41]
N14DNTARnormalimpairedimpairedmoderate[42]
S19TNTARimpaired/defectprofound[33]
R32CTM1ARdefect///[43]
R32HTM1ARdefect//severe/profound[44,45]
I33TTM1ARnormal/defectsevere/profound[46]
M34TTM1ADnormalimpairedimpairedmild/moderate/severe[35,41]
I35STM1ARdefect//severe/profound[46]
V37ITM1ARnormaldefectimpairedmild[41,47,48]
A40GTM1ARnormaldefectdefectprofound[48,49]
W44CEC1ADnormal/Impairedsevere/profound[50,51]
W44SEC1ADimpairedimpairedimpaired/[52,53]
G45REC1ADnormalimpairedimpairedmild[54]
D46EEC1ADnormalimpaireddefectmoderate[34]
E47KEC1ARnormalimpaireddefect/[55,56]
E47QEC1ARnormalimpaireddefect/[56]
T55NEC1AD(YES)defect//severe/profound[57]
G59VEC1ADnormal/defectprofound[58,59]
I71NEC1ARimpairedimpaired/severe/profound[60]
W77R TM2ARdefect//severe/profound[38,50,61]
I82MTM2ARnormaldefect/profound[38,59]
V84LTM2ARnormalnormalimpairedprofound[41,62,63]
S85YTM2ARdefect///[56]
T86RTM2ARdefect//profound[34]
A88STM2ARnormalnormalimpairedprofound[63,64]
L90PTM2ARimpairedimpaired/severe/profound[33,35,38]
V95MTM2ARnormalnormalimpairedprofound[49,62,63]
H100LCLARnormalimpairedimpairedprofound[49,56]
H100YCLARnormalimpairedimpaired/[56]
G109VCLARnormalimpaireddefectprofound[39,65]
S113RCLAR//defect [47]
R127HCLARnormalimpairedimpairedsevere/profound[33,45,56]
R127LCLARnormalimpairedimpaired/[56]
R143QTM3ADnormal/defectprofound[53,66]
R143WTM3AR//defectprofound[37,41]
V153ITM3AR//defectsevere/profound[37,38]
F161SEC2ARimpaired/impaired/[35]
M163LEC2AD(YES)defect//mild/moderate[67]
M163VEC2ADnormal/impairedsevere/profound[24,38]
W172CEC2ARimpairedimpaired/profound[20,68]
W172REC2ARnormal/impaired/[46]
P173REC2ARdefect//severe/profound[35,69]
D179NEC2ARnormal/impairedsevere[53,70]
R184QEC2ADnormal/defectprofound[51,53]
R184PEC2ARdefect//severe/profound[35,44,49]
K188REC2ARdefect///[71]
M195VTM4AD(YES)defect//severe/profound[56,72]
M195TTM4ARnormal/impaired [71]
M195LTM4ARnormalimpairedimpaired/[56]
A197STM4ADnormal/impairedprofound[71,73]
S199FTM4ARdefect//severe/profound[71,74]
G200RTM4ARdefect//severe[71,75]
C202F TM4ADnormalimpairedimpairedmild/moderate[71,76]
I203TTM4ARnormalimpairedimpairedprofound[71,77]
I203KTM4ARdefect//profound[71,73]
L205VTM4ARnormalimpairedimpairedprofound[71,78]
L205PTM4ARdefect//moderate/severe/profound[71,79]
N206STM4ARnormalimpairedimpairedmild/moderate/severe[71,77]
T208PTM4ARdefect///[71]
L214PTM4AR//defectprofound[37,73]
NT: N-term, TM: transmembrane, EC: extracellular loop, CL: cytoplasmic loop, AD: autosomal dominant, AR: autosomal recessive. Defective trafficking: the mutant is completely retained within the cell and cannot traffic to the cell membrane. Impaired trafficking: only a small fraction of the mutant is able to traffic to the cell membrane. The WHO hearing loss classification standard (1997): normal (≤25 dB), mild (26–40 dB), moderate (41–60 dB), severe (61–80 dB), and profound (≥81 dB).
Some mutants can partially traffic to the cell membrane surface, but those that reach the cell membrane are insufficient to form functional GJ channels or functionally impaired GJ channels. The S19T and L90P mutants showed intracellular and cell membrane localization, but the level of GJ plaque formed was low [33]. F161S showed weak membrane localization in immunofluorescence studies, confirming that few of these mutant proteins were transferred to the cytosol [35]. Similarly, the W172C mutant is translocated chiefly to the cell membrane. However, the function is significantly impaired compared to the wildtype, as revealed by propidium iodide (PI) dye loading assay, showing the significantly reduced permeability of the mutated hemichannels [20].
Other mutants can traffic to the cell membrane but form GJ channels with no or impaired functions. The V37I and A40G mutants have similar plasma membrane localization to wildtype Cx26 [48]. However, both mutants were less efficient in forming GJ patches than the wildtype. Moreover, none formed functional hemichannels at low extracellular calcium. Kim et al. evaluated seven of ten Cx26 mutants that could translocate to the plasma membrane to form GJ plaques and found that E47K, E47Q, H100L, H100Y, and R127L did not function normally as homo-oligomeric GJ channels [56]. However, all seven variants could function normally as hetero-oligomeric GJ channels. When the mutants formed a heteromeric connexon with wildtype Cx26, the ionic coupling of the GJ channels did not significantly differ from that of the GJs composed of wildtype Cx26 alone.
In conclusion, trafficking defects, abnormal hemichannel activity, and abnormal GJ channel function are the main pathogenic mechanisms of recessive pathogenic variants. However, most GJB2 missense variants have not been functionally studied, or the functional findings are controversial. Therefore, further studies are needed to determine the underlying molecular mechanisms and guide clinical diagnosis and treatment.

4.1.2. Nonsyndromic HL Caused by GJB2 Dominant Variants

Compared to recessive Cx26 variants, few dominant pathogenic variants have been identified that cause nonsyndromic HL. These dominant variants only alter the function of the mutant protein; they do not affect wildtype or other coexpressed proteins and therefore only cause nonsyndromic HL. There are 14 GJB2 nonsyndromic dominant variants in the TM1 (1/14), EC1 (6/14), TM3 (1/14), EC2 (3/14), and TM4 (3/14) structural domains. They include three variants showing trafficking defects, one showing impaired trafficking, and ten showing normal trafficking to the cell membrane (Table 1).
The nonsyndromic dominant variants include three mutants with trafficking defects. In cells transfected with the T55N-EYFP mutant, EYFP localized intracellularly, indicating that the mutation impaired protein trafficking to the plasma membrane [57]. However, the mutant protein M163L was not trafficked to the plasma membrane but did traffic to the cell membrane, where it co-localized with the wildtype Cxs when coexpressed with wtCx26 or wtCx30 [67]. Cells expressing M163L alone acquired a rounded and detached morphology, suggesting the mutant was associated with increased cell death. Another dominant mutant, M195L, remained in the cytoplasm, particularly in the ER, and could not traffic to the cell membrane [56].
Only one nonsyndromic dominant variant, W44S, has been functionally investigated and has impaired trafficking. W44S resulted in a protein localized to the membrane and dispersed intracellularly [52]. However, dye transfer studies have revealed a significant decrease in the ability of the W44S mutant to transfer neurobiotin to neighboring cells, which implies a compromised ability of the mutant protein to form normal functional channels. Usually, variants that cause nonsyndromic HL do not adversely affect wildtype proteins. However, W44S produces proteins with a dominant negative effect on Cx26 and Cx30 [52]. Sabrina et al. obtained the same results where mutants coexpressed with Cx26 and Cx30 did not transfer Lucifer Yellow dye [53].
Nine variants have normal trafficking capacities to the cell membrane. The M34T mutant has strong membrane localization, but the hemichannel assembly is disrupted, and a neurobiotin injection showed decreased tracer coupling in M34T transfectants [35]. The G46E mutant exhibits similar cell membrane localization to the wildtype Cx26 and can co-assemble with it into GJ channels but with reduced hemichannel activity and biochemical coupling [34]. Other dominant variants with similar pathogenic mechanisms are W44C, G45R, G59V, R143Q, R184Q, A197S, and C202F.
Dominant variants causing nonsyndromic HL do not induce cell death. However, in an in vitro study, the M163L mutant protein targeted the plasma membrane with a trafficking defect and was associated with increased cell death [67]. M163L is the only pathogenic variant identified in nonsyndromic HL that causes cell death. Therefore, the increased cell death is a pathogenic mechanism leading to nonsyndromic HL that needs further study.

4.1.3. Relationship between Variants Causing Nonsyndromic HL and Clinical Phenotype

In clinical practice, GJB2 pathogenic missense variants can lead to varying degrees of HL. Nonsyndromic HL due to GJB2 recessive missense variants is primarily congenital, bilaterally symmetric, and non-progressive, with severe-to-profound severity. However, some variants cause mild to moderate HL. Recessive variants might lead to milder phenotypes due to their compound heterozygous partners. Compound heterozygosity with truncating variants may lead to more severe phenotypes, whereas missense variants that do not have serious consequences may lead to less severe HL [80]. Dominant variants cause mainly postlingual progressive hearing loss. Dominant variants, such as G45R, may cause milder HL because the mutant can traffic to the cell membrane with only partially impaired hemichannel or GJC function [54]. On the other hand, the M163L variant cannot traffic itself, but when co-expressed with the wildtype Cx26, it can traffic to the cell membrane, thus leading to a milder phenotype [67].
V37I can cause mild to moderate sensorineural HL. A review of the synthesized information of the ClinGen Hearing Loss Expert Panel identified significant overexpression of the V37I variant in HL patients compared to the normal population. The panel concluded that the V37I variant in GJB2 is pathogenic for autosomal recessive nonsyndromic HL with variable expressivity and incomplete penetrance [81]. The biallelic p.V37I variant is associated with steadily progressive HL with increasing incidence over time, and most biallelic p.V37I individuals may develop significant HL in later adulthood [82].

4.2. Syndromic HL Caused by GJB2 Missense Variants

4.2.1. Syndromic HL Caused by GJB2 Dominant Variants

More than 20 GJB2 missense variants cause syndromic HL, most of which are dominantly inherited. Functional studies have found that dominant syndromic variants are not present in the C-terminal and EC2 structural domains but are clustered in the N-terminal (5/21) and EC1 (9/21) structural domains, and in the TM1 (2/21), TM2 (3/21), TM3 (1/21), and TM4 (1/21) structural domains, respectively. Variants causing syndromic phenotypes are usually located at conserved amino acid sites and cause more severe phenotypes than dominant variants causing nonsyndromic HL. Moreover, the mechanisms causing syndromic HL are not identical to those causing nonsyndromic HL. Besides trafficking defects, abnormal hemichannel, and GJ channel functions, most dominant variants induce cell death or have dominant-negative or trans-dominant effects on wildtype and other Cxs, resulting in HL combined with a skin disease (Table 2).
Compared to pathogenic variants causing nonsyndromic HL, pathogenic variants that cause syndromic HL usually lead to increased hemichannel activity. However, some mutant proteins have impaired hemichannel activity; for example, the S17F variant resulted in a complete loss of hemichannel activity [85]. Dye uptake assays showed that cells expressing the N54K mutant demonstrated a highly variable incidence of PI uptake, and cells expressing the S183F mutant displayed no increase in PI uptake, indicating nonfunctional hemichannels [24]. Marziano et al. [52] and Albuloushi et al. [87] obtained similar results for the hemichannel activity of the D66H and F142L mutants. Both variants resulted in syndromic HL and had reduced hemichannel activity.
A common feature of syndromic HL is increased induction of cell death. Six known variants induce increased cell death. In experiments, 53% of cells transfected with the G11E mutant died after 24 h; however, only 13% of cells transfected with the wildtype died [83]. Cells expressing G12R, N14K, and D50N experienced increased cell death that correlated with larger hemichannel currents than the wild-type-expressing cells [85]. Gerido et al. [91] proved that Cx26-G45E hemichannels displayed significantly greater whole-cell currents than wildtype Cx26, leading to cell lysis and death. A40V produced abnormal hemichannel activity when expressed in Xenopus oocytes, eventually leading to cell lysis and death [92].
Another distinctive feature of variants causing syndromic HL is a dominant-negative or trans-dominant effect on wildtype Cx26 or other Cxs. For example, HeLa cells cotransfected with G45R and wildtype Cx26 could form GJs, whereas G45E (causing nonsyndromic HL) and wildtype Cx26 did not [54]. The N54K mutant protein was retained intracellularly and displayed a dominant or transdominant effect on wildtype Cx26 and coexpressed Cx30 and Cx43. The S183F mutant formed some GJ plaques but was primarily retained within the cell and exhibited only a mild trans-dominant effect on coexpressed Cx30 [24]. Coexpression of the S183F and H73R mutants with wildtype Cx43 showed trans-dominant inhibition of Cx43 GJs, without affecting Cx43 protein synthesis [95]. R75W had a dominant negative effect on wildtype Cx26 [46] and a trans-dominant effect on wildtype Cx30 [52]; however, R75Q only had a trans- dominant effect on wildtype Cx30 [53]. Similarly, the dominant actions of the G59A and D66H mutants were only on Cx30 and Cx26, respectively [52].
Other dominant pathogenic variants that cause syndromic HL, such as I30N, D50A, and D50Y, have only been explored regarding whether they can traffic properly and have hemichannel functions. It is unclear whether the pathogenic variants affect cell death, or wildtype and other connexins proteins. Therefore, further studies are needed to elucidate clear pathogenesis.

4.2.2. Relationship between Pathogenic Variants Causing Syndromic HL and Clinical Phenotypes

Syndromic variants in Cx26 are associated with various skin disorders and always present with autosomal dominant inheritance. The features of syndromic HL usually include sensorineural HL and various epidermal abnormalities such as palmoplantar keratosis (thickened skin on the palms and soles of the feet), knuckle pads, finger (toe) nail abnormalities, ichthyosis, and false hoop toe/toe breaks [32].
Pathogenic variants associated with cell death and dominant-negative and trans-dominant effects, such as G11E, G45E, and H73R, usually lead to more severe phenotypes such as KID syndrome or PPK. Pathogenic variants without these features generally cause only the milder phenotype of Vohwinkel syndrome. However, several pathogenic variants, including N14K, I30N, and D50A, did not induce cell death or have dominant negative or trans-dominant effects on wildtype and other connexins. However, they still caused KID syndrome, suggesting that these variants may have other pathogenic mechanisms that require further exploration (Table 2).

5. The Gap between Possible and Functionally Studied Missense Variants of the GJB2 Gene

With the development of high-throughput sequencing technology, genetic testing strategies, such as target gene sequencing and whole-exome sequencing, are widely used to diagnose the causes of HL. These will promote the prevention and treatment outcomes of genetic deafness. In addition, joint newborn hearing and genetic screening for HL can significantly improve the benefits of hearing screening in China [2,3]. Medical geneticists classify genetic variants found in genetic testing into five tiers, including pathogenic, likely pathogenic, variants of uncertain significance (VUS), likely benign, or benign based on the ACMG guidelines [98]. On the other hand, the advancement of genetic testing technologies also results in more VUSs due to the increased number of genes being analyzed, which hinders HL prevention and control.
The GJB2 gene is the most prevalent gene responsible for HL worldwide. Although less common than truncating variants, missense variants are the most abundant variant type of the GJB2 gene [99]. Cx26 contains 226 amino acid residues, and each residue can be mutated to one of the other 19 amino acids; therefore, there are 4294 possible missense variants. Of these 4294 variants, 1334 can be achieved by a single base pair variant in a codon (simple missense variants), while 2960 can only be achieved by variant in more than two bases in a codon (complex variants) (Figure 4). We have compiled a comprehensive dataset of GJB2 missense variants based on public databases, including HGMD, Clinvar, and the Deafness Variation Database, and literature articles [99]. We have classified these 1334 simple missense variants into five tiers (Supplemental Table S1), and approximately 84.2% of missense variants are VUS (Figure 4). Information on the effects of all VUSs on Cx26 is required to guide clinical diagnosis, treatment, and prevention.
Simple missense variants were defined as missense variants that can be achieved by a single base pair variant in a codon, while complex ones can only be achieved by a variant in more than two bases in a codon. Each column indicates one amino acid (AA) residue in Cx26 (upper panel: 1–113, lower panel: 114–226). The 20 rows represent all 20 possible AA substitutions. WT, wildtype: white; Com, complex missense variants: grey; B: Benign; LB: likely Benign; VUS: Variants of Uncertain Significance; LP: Likely Pathogenic; P: Pathogenic.
It is impossible to rapidly determine the functions of the many possible GJB2 VUSs, because the traditional experimental methods of overexpressing mutants in cell lines waste manpower and resources. An alternative solution is to predict pathogenicity using computational methods, which can predict the effects of the missense variants on a large scale. However, based on sequence homology, protein structure, and evolutionary conservation, these computational methods have their merits and limitations, and optimal tool selection is not always possible [100].
Another high-throughput method to solve VUSs is deep mutational scanning (DMS) [101], which is possible due to the development of synthetic DNA technology and the decreasing sequencing costs. DMS technology has been widely used to study the function of variants in clinically actionable genes, such as BRCA1 [102], PPARG [103], TP53 [104], NUDT15 [105], MSH2 [106], and EGFR [107]. DMS includes three parts: the construction of a variant library; the identification and validation of the selection system for the protein function of interest and the introduction of the variant library into the selection system and subjected to selection; and the calculation of a functional score for each variant based on the change in the frequency of the variant during the selection [108] (Figure 5). Among the three parts, selection system, i.e., functional assays, needs to be properly designed and validated. Several commonly used functional assays are widely applied in DMS, such as cytotoxicity assays implemented in studying EGFR [107] and SCN5A variants [109], protein affinity assay in studying functional interaction sites in CXCR4 and CCR5 [110], reporter assay in ADRB2 study [111], and resting membrane potential assay for a K+ channel KCNJ2 [112]. For the GJB2 gene, a library of all possible 4294 missense variants will be created and subjected to the selection system. The selection system will mainly focus on the trafficking of connexin, hemichannel activity, GJC function, cell death, and dominant-negative or trans-dominant effects on coexpressed Cxs. Applying DMS to the GJB2 gene will elucidate the molecular mechanisms by which different GJB2 missense variants cause different clinical HL phenotypes and promote the application of genetic testing in HL prevention and control.

6. Conclusions

GJB2 is one of the most important genes responsible for hearing loss, and missense variants are the most abundant variant type. Pathogenic missense variants can lead to both nonsyndromic and syndromic hearing loss combined with skin diseases; however, the molecular mechanisms leading to the different clinical phenotypes are not fully understood. We have summarized the 84 missense variants that have been functionally studied and investigated the molecular mechanisms that affected hemichannel and gap junction functions, including connexin biosynthesis, trafficking, oligomerization into connexons, permeability, and interactions between other coexpressed connexins. We have also compiled a comprehensive dataset of GJB2 missense variants from public databases and published literature and found that most missense variants have not been functionally studied and have been rated as variants of unknown significance. Therefore, with the recently developed deep mutational scanning technology, which draws on high-throughput DNA sequencing to assess the functional capacity of a large number of variants of a protein simultaneously [101], we hope to elucidate the functional consequence for all possible GJB2 missense variants. These results will help to reveal the mechanisms by which different missense variants cause different phenotypes and to provide guidance for genetic counseling and deafness prevention and control.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/biology12040505/s1, Table S1: The final classification and relevant information in other databases or literature for all 1334 missense variants in the GJB2 gene.

Author Contributions

Formal analysis, L.M. and B.Z.; conceptualization, Y.W. (Yueqiang Wang), L.A. and H.X.; interpretation data/result, L.M., B.Z., M.L. and Y.C.; data collection and curation, Y.W. (Yanyan Wang), M.L. and Y.C.; project administration and supervision, D.F., W.T., and H.X.; methodology, Y.W. (Yueqiang Wang), L.A. and Y.W. (Yanyan Wang); phenotype analysis, Y.W. (Yanyan Wang); resources, W.T.; visualization, D.F., M.L. and Y.C.; technical, material support, D.F. writing-original draft, L.M., L.A., B.Z. and H.X.; writing-review&editing, L.M., Y.W. (Yueqiang Wang), D.F., W.T. and H.X.; funding acquisition, H.X. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (82101963).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

Figure 1, Figure 2, Figure 3 and Figure 5 were created with BioRender.com (accessed on 19 January 2022).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. World Health Organization. Deafness and Hearing Loss. 2021. Available online: https://www.who.int/news-room/fact-sheets/detail/deafness-and-hearing-loss (accessed on 31 December 2021).
  2. Wang, Q.; Xiang, J.; Sun, J.; Yang, Y.; Guan, J.; Wang, D.; Song, C.; Guo, L.; Wang, H.; Chen, Y.; et al. Nationwide population genetic screening improves outcomes of newborn screening for hearing loss in China. Genet. Med. 2019, 21, 2231–2238. [Google Scholar] [CrossRef] [PubMed]
  3. Dai, P.; Huang, L.H.; Wang, G.J.; Gao, X.; Qu, C.Y.; Chen, X.W.; Ma, F.R.; Zhang, J.; Xing, W.L.; Xi, S.Y.; et al. Concurrent Hearing and Genetic Screening of 180,469 Neonates with Follow-up in Beijing, China. Am. J. Hum. Genet. 2019, 105, 803–812. [Google Scholar] [CrossRef] [Green Version]
  4. Morton, C.C.; Nance, W.E. Current concepts: Newborn hearing screening—A silent revolution. N. Engl. J. Med. 2006, 354, 2151–2164. [Google Scholar] [CrossRef] [PubMed]
  5. Michalski, N.; Petit, C. Genes Involved in the Development and Physiology of Both the Periphera l and Central Auditory Systems. Annu. Rev. Neurosci. 2019, 42, 67–86. [Google Scholar] [CrossRef]
  6. Chan, D.K.; Chang, K.W. GJB2-associated hearing loss: Systematic review of worldwide prevalence, genotype, and auditory phenotype. Laryngoscope 2014, 124, E34–E53. [Google Scholar] [CrossRef]
  7. Srinivas, M.; Verselis, V.K.; White, T.W. Human diseases associated with connexin mutations. Biochim. Biophys. Acta Biomembr. 2018, 1860, 192–201. [Google Scholar] [CrossRef]
  8. Maeda, S.; Nakagawa, S.; Suga, M.; Yamashita, E.; Oshima, A.; Fujiyoshi, Y.; Tsukihara, T. Structure of the connexin 26 gap junction channel at 3.5 A resolution. Nature 2009, 458, 597–602. [Google Scholar] [CrossRef] [PubMed]
  9. Martínez, A.D.; Acuña, R.; Figueroa, V.; Maripillan, J.; Nicholson, B. Gap-junction channels dysfunction in deafness and hearing loss. Antioxid. Redox Signal. 2009, 11, 309–322. [Google Scholar] [CrossRef] [Green Version]
  10. Kumar, N.M.; Gilula, N.B. The gap junction communication channel. Cell 1996, 84, 381–388. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  11. Li, X.; Kamasawa, N.; Ciolofan, C.; Olson, C.O.; Lu, S.; Davidson, K.G.; Yasumura, T.; Shigemoto, R.; Rash, J.E.; Nagy, J.I. Connexin45-containing neuronal gap junctions in rodent retina also contain connexin36 in both apposing hemiplaques, forming bihomotypic gap junctions, with scaffolding contributed by zonula occludens-1. J. Neurosci. 2008, 28, 9769–9789. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Koval, M.; Molina, S.A.; Burt, J.M. Mix and match: Investigating heteromeric and heterotypic gap junction channels in model systems and native tissues. FEBS Lett. 2014, 588, 1193–1204. [Google Scholar] [CrossRef] [Green Version]
  13. Wei, C.J.; Xu, X.; Lo, C.W. Connexins and cell signaling in development and disease. Annu. Rev. Cell Dev. Biol. 2004, 20, 811–838. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Van Campenhout, R.; Gomes, A.R.; De Groof, T.W.M.; Muyldermans, S.; Devoogdt, N.; Vinken, M. Mechanisms Underlying Connexin Hemichannel Activation in Disease. Int. J. Mol. Sci. 2021, 22, 3503. [Google Scholar] [CrossRef] [PubMed]
  15. Gabriel, H.D.; Jung, D.; Bützler, C.; Temme, A.; Traub, O.; Winterhager, E.; Willecke, K. Transplacental uptake of glucose is decreased in embryonic lethal connexin26-deficient mice. J. Cell Biol. 1998, 140, 1453–1461. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Lv, J.; Fu, X.; Li, Y.; Hong, G.; Li, P.; Lin, J.; Xun, Y.; Fang, L.; Weng, W.; Yue, R.; et al. Deletion of Kcnj16 in Mice Does Not Alter Auditory Function. Front. Cell Dev. Biol. 2021, 9, 630361. [Google Scholar] [CrossRef] [PubMed]
  17. Xie, L.; Chen, S.; Xu, K.; Cao, H.Y.; Du, A.N.; Bai, X.; Sun, Y.; Kong, W.J. Reduced postnatal expression of cochlear Connexin26 induces hearing loss and affects the developmental status of pillar cells in a dose-dependent manner. Neurochem. Int. 2019, 128, 196–205. [Google Scholar] [CrossRef]
  18. Chen, P.; Wu, W.; Zhang, J.; Chen, J.; Li, Y.; Sun, L.; Hou, S.; Yang, J. Pathological mechanisms of connexin26-related hearing loss: Potassium recycling, ATP-calcium signaling, or energy supply? Front. Mol. Neurosci. 2022, 15, 976388. [Google Scholar] [CrossRef]
  19. Laird, D.W. Life cycle of connexins in health and disease. Biochem. J. 2006, 394, 527–543. [Google Scholar] [CrossRef] [Green Version]
  20. Maslova, E.A.; Orishchenko, K.E.; Posukh, O.L. Functional Evaluation of a Rare Variant c.516G>C (p.Trp172Cys) in the GJB2 (Connexin 26) Gene Associated with Nonsyndromic Hearing Loss. Biomolecules 2021, 11, 61. [Google Scholar] [CrossRef]
  21. Laird, D.W.; Naus, C.C.; Lampe, P.D. SnapShot: Connexins and Disease. Cell 2017, 170, 1260–1260. [Google Scholar] [CrossRef] [PubMed]
  22. Del Castillo, F.J.; Del Castillo, I. DFNB1 Non-syndromic Hearing Impairment: Diversity of Mutations and Associated Phenotypes. Front. Mol. Neurosci. 2017, 10, 428. [Google Scholar] [CrossRef] [Green Version]
  23. Wingard, J.C.; Zhao, H.B. Cellular and Deafness Mechanisms Underlying Connexin Mutation-Induced Hearing Loss—A Common Hereditary Deafness. Front. Cell Neurosci. 2015, 9, 202. [Google Scholar] [CrossRef] [Green Version]
  24. Press, E.R.; Shao, Q.; Kelly, J.J.; Chin, K.; Alaga, A.; Laird, D.W. Induction of cell death and gain-of-function properties of connexin26 mutants predict severity of skin disorders and hearing loss. J. Biol. Chem. 2017, 292, 9721–9732. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Iossa, S.; Marciano, E.; Franze, A. GJB2 Gene Mutations in Syndromic Skin Diseases with Sensorineural Hearing Loss. Curr. Genom. 2011, 12, 475–785. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Kelsell, D.P.; Dunlop, J.; Stevens, H.P.; Lench, N.J.; Liang, J.N.; Parry, G.; Mueller, R.F.; Leigh, I.M. Connexin 26 mutations in hereditary non-syndromic sensorineural deafness. Nature 1997, 387, 80–83. [Google Scholar] [CrossRef]
  27. Heathcote, K.; Syrris, P.; Carter, N.D.; Patton, M.A. A connexin 26 mutation causes a syndrome of sensorineural hearing loss and palmoplantar hyperkeratosis (MIM 148350). J. Med. Genet. 2000, 37, 50–51. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Maestrini, E.; Korge, B.P.; Ocana-Sierra, J.; Calzolari, E.; Cambiaghi, S.; Scudder, P.M.; Hovnanian, A.; Monaco, A.P.; Munro, C.S. A missense mutation in connexin26, D66H, causes mutilating keratoderma with sensorineural deafness (Vohwinkel’s syndrome) in three unrelated families. Hum. Mol. Genet. 1999, 8, 1237–1243. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  29. Richard, G.; Rouan, F.; Willoughby, C.E.; Brown, N.; Chung, P.; Ryynänen, M.; Jabs, E.W.; Bale, S.J.; DiGiovanna, J.J.; Uitto, J.; et al. Missense mutations in GJB2 encoding connexin-26 cause the ectodermal dysplasia keratitis-ichthyosis-deafness syndrome. Am. J. Hum. Genet. 2002, 70, 1341–1348. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  30. van Geel, M.; van Steensel, M.A.; Küster, W.; Hennies, H.C.; Happle, R.; Steijlen, P.M.; König, A. HID and KID syndromes are associated with the same connexin 26 mutation. Br. J. Derm. 2002, 146, 938–942. [Google Scholar] [CrossRef] [PubMed]
  31. Richard, G.; Brown, N.; Ishida-Yamamoto, A.; Krol, A. Expanding the phenotypic spectrum of Cx26 disorders: Bart-Pumphrey syndrome is caused by a novel missense mutation in GJB2. J. Investig. Derm. 2004, 123, 856–863. [Google Scholar] [CrossRef] [Green Version]
  32. Avshalumova, L.; Fabrikant, J.; Koriakos, A. Overview of skin diseases linked to connexin gene mutations. Int J. Derm. 2014, 53, 192–205. [Google Scholar] [CrossRef] [PubMed]
  33. D’Andrea, P.; Veronesi, V.; Bicego, M.; Melchionda, S.; Zelante, L.; Di Iorio, E.; Bruzzone, R.; Gasparini, P. Hearing loss: Frequency and functional studies of the most common connexin26 alleles. Biochem. Biophys. Res. Commun. 2002, 296, 685–691. [Google Scholar] [CrossRef]
  34. Choi, S.Y.; Park, H.J.; Lee, K.Y.; Dinh, E.H.; Chang, Q.; Ahmad, S.; Lee, S.H.; Bok, J.; Lin, X.; Kim, U.K. Different functional consequences of two missense mutations in the GJB2 gene associated with non-syndromic hearing loss. Hum. Mutat. 2009, 30, E716–E727. [Google Scholar] [CrossRef] [PubMed]
  35. Thönnissen, E.; Rabionet, R.; Arbonès, M.L.; Estivill, X.; Willecke, K.; Ott, T. Human connexin26 (GJB2) deafness mutations affect the function of gap junction channels at different levels of protein expression. Hum. Genet. 2002, 111, 190–197. [Google Scholar] [CrossRef]
  36. Bajaj, Y.; Sirimanna, T.; Albert, D.M.; Qadir, P.; Jenkins, L.; Bitner-Glindzicz, M. Spectrum of GJB2 mutations causing deafness in the British Bangladeshi population. Clin. Otolaryngol. 2008, 33, 313–318. [Google Scholar] [CrossRef] [PubMed]
  37. Meşe, G.; Londin, E.; Mui, R.; Brink, P.R.; White, T.W. Altered gating properties of functional Cx26 mutants associated with recessive non-syndromic hearing loss. Hum. Genet. 2004, 115, 191–199. [Google Scholar] [CrossRef]
  38. Dalamon, V.; Beheran, A.; Diamante, F.; Pallares, N.; Diamante, V.; Elgoyhen, A.B. Prevalence of GJB2 mutations and the del(GJB6-D13S1830) in Argentinean non-syndromic deaf patients. Hear. Res. 2005, 207, 43–49. [Google Scholar] [CrossRef]
  39. Dalamon, V.; Fiori, M.C.; Figueroa, V.A.; Oliva, C.A.; Del Rio, R.; Gonzalez, W.; Canan, J.; Elgoyhen, A.B.; Altenberg, G.A.; Retamal, M.A. Gap-junctional channel and hemichannel activity of two recently identified connexin 26 mutants associated with deafness. Pflug. Arch. 2016, 468, 909–918. [Google Scholar] [CrossRef]
  40. Dalamón, V.; Lotersztein, V.; Béhèran, A.; Lipovsek, M.; Diamante, F.; Pallares, N.; Francipane, L.; Frechtel, G.; Paoli, B.; Mansilla, E.; et al. GJB2 and GJB6 genes: Molecular study and identification of novel GJB2 mutations in the hearing-impaired Argentinean population. Audiol. Neurootol. 2010, 15, 194–202. [Google Scholar] [CrossRef]
  41. Kenna, M.A.; Wu, B.L.; Cotanche, D.A.; Korf, B.R.; Rehm, H.L. Connexin 26 studies in patients with sensorineural hearing loss. Arch. Otolaryngol. Head Neck Surg. 2001, 127, 1037–1042. [Google Scholar] [CrossRef] [Green Version]
  42. Haack, B.; Schmalisch, K.; Palmada, M.; Bohmer, C.; Kohlschmidt, N.; Keilmann, A.; Zechner, U.; Limberger, A.; Beckert, S.; Zenner, H.P.; et al. Deficient membrane integration of the novel p.N14D-GJB2 mutant associated with non-syndromic hearing impairment. Hum. Mutat. 2006, 27, 1158–1159. [Google Scholar] [CrossRef]
  43. Li, J.-Z.; Hu, Y.-Q.; Wang, S.-H.; Cheng, H.-S.; Pan, Q.; Xia, K.; Hu, Z.-M.; Feng, Y. Mutations of Cx26 gene in patients with NSHL and intracellular distrib ution of two mutants. Yi Chuan = Hereditas 2009, 31, 705–712. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Beach, R.; Abitbol, J.M.; Allman, B.L.; Esseltine, J.L.; Shao, Q.; Laird, D.W. GJB2 Mutations Linked to Hearing Loss Exhibit Differential Trafficking and Functional Defects as Revealed in Cochlear-Relevant Cells. Front. Cell Dev. Biol. 2020, 8, 215. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Mahdieh, N.; Mahmoudi, H.; Ahmadzadeh, S.; Bakhtiyari, S. GJB2 mutations in deaf population of Ilam (Western Iran): A different pattern of mutation distribution. Eur. Arch. Otorhinolaryngol. 2016, 273, 1161–1165. [Google Scholar] [CrossRef] [PubMed]
  46. Mani, R.S.; Ganapathy, A.; Jalvi, R.; Srikumari Srisailapathy, C.R.; Malhotra, V.; Chadha, S.; Agarwal, A.; Ramesh, A.; Rangasayee, R.R.; Anand, A. Functional consequences of novel connexin 26 mutations associated with hereditary hearing loss. Eur. J. Hum. Genet. 2009, 17, 502–509. [Google Scholar] [CrossRef] [Green Version]
  47. Bruzzone, R.; Veronesi, V.; Gomès, D.; Bicego, M.; Duval, N.; Marlin, S.; Petit, C.; D’Andrea, P.; White, T.W. Loss-of-function and residual channel activity of connexin26 mutations associated with non-syndromic deafness. FEBS Lett. 2003, 533, 79–88. [Google Scholar] [CrossRef] [Green Version]
  48. Jara, O.; Acuña, R.; García, I.E.; Maripillán, J.; Figueroa, V.; Sáez, J.C.; Araya-Secchi, R.; Lagos, C.F.; Pérez-Acle, T.; Berthoud, V.M.; et al. Critical role of the first transmembrane domain of Cx26 in regulating oligomerization and function. Mol. Biol. Cell 2012, 23, 3299–3311. [Google Scholar] [CrossRef]
  49. Primignani, P.; Trotta, L.; Castorina, P.; Lalatta, F.; Sironi, F.; Radaelli, C.; Degiorgio, D.; Curcio, C.; Travi, M.; Ambrosetti, U.; et al. Analysis of the GJB2 and GJB6 genes in Italian patients with nonsyndromic hearing loss: Frequencies, novel mutations, genotypes, and degree of hearing loss. Genet. Test. Mol. Biomark. 2009, 13, 209–217. [Google Scholar] [CrossRef]
  50. Martin, P.E.; Coleman, S.L.; Casalotti, S.O.; Forge, A.; Evans, W.H. Properties of connexin26 gap junctional proteins derived from mutations associated with non-syndromal heriditary deafness. Hum. Mol. Genet. 1999, 8, 2369–2376. [Google Scholar] [CrossRef] [Green Version]
  51. Welch, K.O.; Marin, R.S.; Pandya, A.; Arnos, K.S. Compound heterozygosity for dominant and recessive GJB2 mutations: Effect on phenotype and review of the literature. Am. J. Med. Genet. A 2007, 143, 1567–1573. [Google Scholar] [CrossRef]
  52. Marziano, N.K.; Casalotti, S.O.; Portelli, A.E.; Becker, D.L.; Forge, A. Mutations in the gene for connexin 26 (GJB2) that cause hearing loss have a dominant negative effect on connexin 30. Hum. Mol. Genet. 2003, 12, 805–812. [Google Scholar] [CrossRef] [Green Version]
  53. Yum, S.W.; Zhang, J.; Scherer, S.S. Dominant connexin26 mutants associated with human hearing loss have trans-dominant effects on connexin30. Neurobiol. Dis. 2010, 38, 226–236. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Rodriguez-Paris, J.; Waldhaus, J.; Gordhandas, J.A.; Pique, L.; Schrijver, I. Comparative functional characterization of novel non-syndromic GJB2 gene variant p.Gly45Arg and lethal syndromic variant p.Gly45Glu. PeerJ 2016, 4, e2494. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. Stong, B.C.; Chang, Q.; Ahmad, S.; Lin, X. A novel mechanism for connexin 26 mutation linked deafness: Cell death caused by leaky gap junction hemichannels. Laryngoscope 2006, 116, 2205–2210. [Google Scholar] [CrossRef]
  56. Kim, H.R.; Oh, S.K.; Lee, E.S.; Choi, S.Y.; Roh, S.E.; Kim, S.J.; Tsukihara, T.; Lee, K.Y.; Jeon, C.J.; Kim, U.K. The pathological effects of connexin 26 variants related to hearing loss by in silico and in vitro analysis. Hum. Genet. 2016, 135, 287–298. [Google Scholar] [CrossRef] [PubMed]
  57. Melchionda, S.; Bicego, M.; Marciano, E.; Franze, A.; Morgutti, M.; Bortone, G.; Zelante, L.; Carella, M.; D’Andrea, P. Functional characterization of a novel Cx26 (T55N) mutation associated to non-syndromic hearing loss. Biochem. Biophys. Res. Commun. 2005, 337, 799–805. [Google Scholar] [CrossRef]
  58. Toth, T.; Kupka, S.; Haack, B.; Riemann, K.; Braun, S.; Fazakas, F.; Zenner, H.P.; Muszbek, L.; Blin, N.; Pfister, M.; et al. GJB2 mutations in patients with non-syndromic hearing loss from Northeastern Hungary. Hum. Mutat. 2004, 23, 631–632. [Google Scholar] [CrossRef]
  59. Palmada, M.; Schmalisch, K.; Böhmer, C.; Schug, N.; Pfister, M.; Lang, F.; Blin, N. Loss of function mutations of the GJB2 gene detected in patients with DFNB1-associated hearing impairment. Neurobiol. Dis. 2006, 22, 112–118. [Google Scholar] [CrossRef]
  60. Mohamed, M.R.; Alesutan, I.; Föller, M.; Sopjani, M.; Bress, A.; Baur, M.; Salama, R.H.; Bakr, M.S.; Mohamed, M.A.; Blin, N.; et al. Functional analysis of a novel I71N mutation in the GJB2 gene among Southern Egyptians causing autosomal recessive hearing loss. Cell Physiol. Biochem. 2010, 26, 959–966. [Google Scholar] [CrossRef]
  61. Richard, G.; White, T.W.; Smith, L.E.; Bailey, R.A.; Compton, J.G.; Paul, D.L.; Bale, S.J. Functional defects of Cx26 resulting from a heterozygous missense mutation in a family with dominant deaf-mutism and palmoplantar keratoderma. Hum. Genet. 1998, 103, 393–399. [Google Scholar] [CrossRef]
  62. Wang, H.L.; Chang, W.T.; Li, A.H.; Yeh, T.H.; Wu, C.Y.; Chen, M.S.; Huang, P.C. Functional analysis of connexin-26 mutants associated with hereditary recessive deafness. J. Neurochem. 2003, 84, 735–742. [Google Scholar] [CrossRef]
  63. Zhang, Y.; Tang, W.; Ahmad, S.; Sipp, J.A.; Chen, P.; Lin, X. Gap junction-mediated intercellular biochemical coupling in cochlear supporting cells is required for normal cochlear functions. Proc. Natl. Acad. Sci. USA 2005, 102, 15201–15206. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  64. Koenighofer, M.; Lucas, T.; Parzefall, T.; Ramsebner, R.; Schoefer, C.; Frei, K. The promoter mutation c.-259C>T (-3438C>T) is not a common cause of non-syndromic hearing impairment in Austria. Eur. Arch. Otorhinolaryngol. 2015, 272, 229–232. [Google Scholar] [CrossRef]
  65. Dalamon, V.; Lotersztein, V.; Lipovsek, M.; Beheran, A.; Mondino, M.E.; Diamante, F.; Pallares, N.; Diamante, V.; Elgoyhen, A.B. Performance of speech perception after cochlear implantation in DFNB1 patients. Acta Otolaryngol. 2009, 129, 395–398. [Google Scholar] [CrossRef]
  66. Riahi, Z.; Zainine, R.; Mellouli, Y.; Hannachi, R.; Bouyacoub, Y.; Laroussi, N.; Beltaief, N.; Kefi, R.; Romdhane, L.; Bonnet, C.; et al. Compound heterozygosity for dominant and recessive GJB2 mutations in a Tunisian family and association with successful cochlear implant outcome. Int. J. Pediatr. Otorhinolaryngol. 2013, 77, 1481–1484. [Google Scholar] [CrossRef] [PubMed]
  67. Matos, T.D.; Caria, H.; Simoes-Teixeira, H.; Aasen, T.; Dias, O.; Andrea, M.; Kelsell, D.P.; Fialho, G. A novel M163L mutation in connexin 26 causing cell death and associated with autosomal dominant hearing loss. Hear. Res. 2008, 240, 87–92. [Google Scholar] [CrossRef] [PubMed]
  68. Posukh, O.; Pallares-Ruiz, N.; Tadinova, V.; Osipova, L.; Claustres, M.; Roux, A.F. First molecular screening of deafness in the Altai Republic population. BMC Med. Genet. 2005, 6, 12. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  69. Rabionet, R.; Zelante, L.; López-Bigas, N.; D’Agruma, L.; Melchionda, S.; Restagno, G.; Arbonés, M.L.; Gasparini, P.; Estivill, X. Molecular basis of childhood deafness resulting from mutations in the GJB2 (connexin 26) gene. Hum. Genet. 2000, 106, 40–44. [Google Scholar] [PubMed]
  70. Primignani, P.; Castorina, P.; Sironi, F.; Curcio, C.; Ambrosetti, U.; Coviello, D.A. A novel dominant missense mutation--D179N--in the GJB2 gene (Connexin 26) associated with non-syndromic hearing loss. Clin. Genet. 2003, 63, 516–521. [Google Scholar] [CrossRef]
  71. Ambrosi, C.; Walker, A.E.; Depriest, A.D.; Cone, A.C.; Lu, C.; Badger, J.; Skerrett, I.M.; Sosinsky, G.E. Analysis of trafficking, stability and function of human connexin 26 gap junction channels with deafness-causing mutations in the fourth transmembrane helix. PLoS ONE 2013, 8, e70916. [Google Scholar] [CrossRef]
  72. Dai, P.; Yu, F.; Han, B.; Liu, X.; Wang, G.; Li, Q.; Yuan, Y.; Liu, X.; Huang, D.; Kang, D.; et al. GJB2 mutation spectrum in 2,063 Chinese patients with nonsyndromic hearing impairment. J. Transl. Med. 2009, 7, 26. [Google Scholar] [CrossRef] [Green Version]
  73. Hamelmann, C.; Amedofu, G.K.; Albrecht, K.; Muntau, B.; Gelhaus, A.; Brobby, G.W.; Horstmann, R.D. Pattern of connexin 26 (GJB2) mutations causing sensorineural hearing impairment in Ghana. Hum. Mutat. 2001, 18, 84–85. [Google Scholar] [CrossRef]
  74. Tamayo, M.L.; Olarte, M.; Gelvez, N.; Gómez, M.; Frías, J.L.; Bernal, J.E.; Florez, S.; Medina, D. Molecular studies in the GJB2 gene (Cx26) among a deaf population from Bogotá, Colombia: Results of a screening program. Int. J. Pediatr. Otorhinolaryngol. 2009, 73, 97–101. [Google Scholar] [CrossRef] [PubMed]
  75. Bakhchane, A.; Bousfiha, A.; Charoute, H.; Salime, S.; Detsouli, M.; Snoussi, K.; Nadifi, S.; Kabine, M.; Rouba, H.; Dehbi, H.; et al. Update of the spectrum of GJB2 gene mutations in 152 Moroccan families with autosomal recessive nonsyndromic hearing loss. Eur. J. Med. Genet. 2016, 59, 325–329. [Google Scholar] [CrossRef] [PubMed]
  76. Morlé, L.; Bozon, M.; Alloisio, N.; Latour, P.; Vandenberghe, A.; Plauchu, H.; Collet, L.; Edery, P.; Godet, J.; Lina-Granade, G. A novel C202F mutation in the connexin26 gene (GJB2) associated with autosomal dominant isolated hearing loss. J. Med. Genet. 2000, 37, 368–370. [Google Scholar] [CrossRef] [Green Version]
  77. Wu, B.L.; Lindeman, N.; Lip, V.; Adams, A.; Amato, R.S.; Cox, G.; Irons, M.; Kenna, M.; Korf, B.; Raisen, J.; et al. Effectiveness of sequencing connexin 26 (GJB2) in cases of familial or sporadic childhood deafness referred for molecular diagnostic testing. Genet. Med. 2002, 4, 279–288. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  78. Yilmaz, A.; Menevse, S.; Bayazit, Y.; Karamert, R.; Ergin, V.; Menevse, A. Two novel missense mutations in the connexin 26 gene in Turkish patients with nonsyndromic hearing loss. Biochem. Genet. 2010, 48, 248–256. [Google Scholar] [CrossRef]
  79. Leshinsky-Silver, E.; Berman, Z.; Vinkler, C.; Yannov-Sharav, M.; Lev, D. A novel missense mutation in the Connexin 26 gene associated with autosomal recessive sensorineural deafness. Hear. Res. 2005, 202, 258–261. [Google Scholar] [CrossRef] [PubMed]
  80. Zheng, J.; Ying, Z.; Cai, Z.; Sun, D.; He, Z.; Gao, Y.; Zhang, T.; Zhu, Y.; Chen, Y.; Guan, M.X. GJB2 Mutation Spectrum and Genotype-Phenotype Correlation in 1067 Han Chinese Subjects with Non-Syndromic Hearing Loss. PLoS ONE 2015, 10, e0128691. [Google Scholar] [CrossRef]
  81. Shen, J.; Oza, A.M.; Del Castillo, I.; Duzkale, H.; Matsunaga, T.; Pandya, A.; Kang, H.P.; Mar-Heyming, R.; Guha, S.; Moyer, K.; et al. Consensus interpretation of the p.Met34Thr and p.Val37Ile variants in GJB2 by the ClinGen Hearing Loss Expert Panel. Genet. Med. 2019, 21, 2442–2452. [Google Scholar] [CrossRef]
  82. Chen, Y.; Wang, Z.; Jiang, Y.; Lin, Y.; Wang, X.; Wang, Z.; Tang, Z.; Wang, Y.; Wang, J.; Gao, Y.; et al. Biallelic p.V37I variant in GJB2 is associated with increasing incidence of hearing loss with age. Genet. Med. 2022, 24, 915–923. [Google Scholar] [CrossRef] [PubMed]
  83. Terrinoni, A.; Codispoti, A.; Serra, V.; Didona, B.; Bruno, E.; Nistico, R.; Giustizieri, M.; Alessandrini, M.; Campione, E.; Melino, G. Connexin 26 (GJB2) mutations, causing KID Syndrome, are associated with cell death due to calcium gating deregulation. Biochem. Biophys. Res. Commun. 2010, 394, 909–914. [Google Scholar] [CrossRef] [PubMed]
  84. Kozhevnikov, O.; Kralina, S.; Yurasova, Y.; Kenis, V.; Kircher, S.G.; Al Kaissi, A. Progressive Deformity of the Lower Limbs in a Patient with KID (Keratitis-Ichthyosis-Deafness) Syndrome. Case Rep. Orthop. 2020, 2020, 8747392. [Google Scholar] [CrossRef] [PubMed]
  85. Lee, J.R.; Derosa, A.M.; White, T.W. Connexin mutations causing skin disease and deafness increase hemichannel activity and cell death when expressed in Xenopus oocytes. J. Investig. Derm. 2009, 129, 870–878. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  86. García, I.E.; Maripillán, J.; Jara, O.; Ceriani, R.; Palacios-Muñoz, A.; Ramachandran, J.; Olivero, P.; Perez-Acle, T.; González, C.; Sáez, J.C.; et al. Keratitis-ichthyosis-deafness syndrome-associated Cx26 mutants produce nonfunctional gap junctions but hyperactive hemichannels when co-expressed with wild type Cx43. J. Investig. Derm. 2015, 135, 1338–1347. [Google Scholar] [CrossRef] [Green Version]
  87. Albuloushi, A.; Lovgren, M.L.; Steel, A.; Yeoh, Y.; Waters, A.; Zamiri, M.; Martin, P.E. A heterozygous mutation in GJB2 (Cx26F142L) associated with deafness and recurrent skin rashes results in connexin assembly deficiencies. Exp. Derm. 2020, 29, 970–979. [Google Scholar] [CrossRef]
  88. Arita, K.; Akiyama, M.; Aizawa, T.; Umetsu, Y.; Segawa, I.; Goto, M.; Sawamura, D.; Demura, M.; Kawano, K.; Shimizu, H. A novel N14Y mutation in Connexin26 in keratitis-ichthyosis-deafness syndrome: Analyses of altered gap junctional communication and molecular structure of N terminus of mutated Connexin26. Am. J. Pathol. 2006, 169, 416–423. [Google Scholar] [CrossRef] [Green Version]
  89. Aypek, H.; Bay, V.; Meşe, G. Altered cellular localization and hemichannel activities of KID syndrome associated connexin26 I30N and D50Y mutations. BMC Cell Biol. 2016, 17, 5. [Google Scholar] [CrossRef] [Green Version]
  90. Arndt, S.; Aschendorff, A.; Schild, C.; Beck, R.; Maier, W.; Laszig, R.; Birkenhager, R. A novel dominant and a de novo mutation in the GJB2 gene (connexin-26) cause keratitis-ichthyosis-deafness syndrome: Implication for cochlear implantation. Otol. Neurotol. 2010, 31, 210–215. [Google Scholar] [CrossRef]
  91. Gerido, D.A.; DeRosa, A.M.; Richard, G.; White, T.W. Aberrant hemichannel properties of Cx26 mutations causing skin disease and deafness. Am. J. Physiol. Cell Physiol. 2007, 293, C337–C345. [Google Scholar] [CrossRef] [Green Version]
  92. Montgomery, J.R.; White, T.W.; Martin, B.L.; Turner, M.L.; Holland, S.M. A novel connexin 26 gene mutation associated with features of the keratitis-ichthyosis-deafness syndrome and the follicular occlusion triad. J. Am. Acad. Dermatol. 2004, 51, 377–382. [Google Scholar] [CrossRef]
  93. Mhaske, P.V.; Levit, N.A.; Li, L.; Wang, H.Z.; Lee, J.R.; Shuja, Z.; Brink, P.R.; White, T.W. The human Cx26-D50A and Cx26-A88V mutations causing keratitis-ichthyosis-deafness syndrome display increased hemichannel activity. Am. J. Physiol. Cell Physiol. 2013, 304, C1150–C1158. [Google Scholar] [CrossRef]
  94. de Zwart-Storm, E.A.; van Geel, M.; Veysey, E.; Burge, S.; Cooper, S.; Steijlen, P.M.; Martin, P.E.; van Steensel, M.A. A novel missense mutation in GJB2, p.Tyr65His, causes severe Vohwinkel syndrome. Br. J. Derm. 2011, 164, 197–199. [Google Scholar] [CrossRef] [PubMed]
  95. Shuja, Z.; Li, L.; Gupta, S.; Mese, G.; White, T.W. Connexin26 Mutations Causing Palmoplantar Keratoderma and Deafness Interact with Connexin43, Modifying Gap Junction and Hemichannel Properties. J. Investig. Derm. 2016, 136, 225–235. [Google Scholar] [CrossRef] [Green Version]
  96. de Zwart-Storm, E.A.; Hamm, H.; Stoevesandt, J.; Steijlen, P.M.; Martin, P.E.; van Geel, M.; van Steensel, M.A. A novel missense mutation in GJB2 disturbs gap junction protein transport and causes focal palmoplantar keratoderma with deafness. J. Med. Genet. 2008, 45, 161–166. [Google Scholar] [CrossRef]
  97. Guerra, L.; Bergamo, F.; D’Apice, M.R.; Angelucci, F.; di Girolamo, S.; Camerota, L.; Monetta, R.; Annessi, G.; Castiglia, D.; Novelli, G.; et al. Keratoderma-Deafness-Mucocutaneous Syndrome Associated with Phe142Leu in the GJB2 Gene. Acta Derm. Venereol. 2019, 99, 1192–1194. [Google Scholar] [CrossRef] [Green Version]
  98. Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gastier-Foster, J.; Grody, W.W.; Hegde, M.; Lyon, E.; Spector, E.; et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015, 17, 405–424. [Google Scholar] [CrossRef] [Green Version]
  99. Xiang, J.; Sun, X.; Song, N.; Ramaswamy, S.; Abou Tayoun, A.N.; Peng, Z. Comprehensive interpretation of single-nucleotide substitutions in GJB2 reveals the genetic and phenotypic landscape of GJB2-related hearing loss. Hum. Genet. 2022. [CrossRef] [PubMed]
  100. Li, J.; Zhao, T.; Zhang, Y.; Zhang, K.; Shi, L.; Chen, Y.; Wang, X.; Sun, Z. Performance evaluation of pathogenicity-computation methods for missense variants. Nucleic Acids Res. 2018, 46, 7793–7804. [Google Scholar] [CrossRef] [Green Version]
  101. Fowler, D.M.; Fields, S. Deep mutational scanning: A new style of protein science. Nat. Methods 2014, 11, 801–807. [Google Scholar] [CrossRef] [PubMed]
  102. Findlay, G.M.; Daza, R.M.; Martin, B.; Zhang, M.D.; Leith, A.P.; Gasperini, M.; Janizek, J.D.; Huang, X.; Starita, L.M.; Shendure, J. Accurate classification of BRCA1 variants with saturation genome editing. Nature 2018, 562, 217–222. [Google Scholar] [CrossRef]
  103. Majithia, A.R.; Tsuda, B.; Agostini, M.; Gnanapradeepan, K.; Rice, R.; Peloso, G.; Patel, K.A.; Zhang, X.; Broekema, M.F.; Patterson, N.; et al. Prospective functional classification of all possible missense variants in PPARG. Nat. Genet. 2016, 48, 1570–1575. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  104. Giacomelli, A.O.; Yang, X.; Lintner, R.E.; McFarland, J.M.; Duby, M.; Kim, J.; Howard, T.P.; Takeda, D.Y.; Ly, S.H.; Kim, E.; et al. Mutational processes shape the landscape of TP53 mutations in human cancer. Nat. Genet. 2018, 50, 1381–1387. [Google Scholar] [CrossRef] [PubMed]
  105. Suiter, C.C.; Moriyama, T.; Matreyek, K.A.; Yang, W.; Scaletti, E.R.; Nishii, R.; Yang, W.; Hoshitsuki, K.; Singh, M.; Trehan, A.; et al. Massively parallel variant characterization identifies NUDT15 alleles associated with thiopurine toxicity. Proc. Natl. Acad Sci. USA 2020, 117, 5394–5401. [Google Scholar] [CrossRef]
  106. Jia, X.; Burugula, B.B.; Chen, V.; Lemons, R.M.; Jayakody, S.; Maksutova, M.; Kitzman, J.O. Massively parallel functional testing of MSH2 missense variants conferring Lynch syndrome risk. Am. J. Hum. Genet. 2021, 108, 163–175. [Google Scholar] [CrossRef] [PubMed]
  107. An, L.E.I.; Wang, Y.; Wu, G.; Wang, Z.; Shi, Z.; Liu, C.; Wang, C.; Yi, M.; Niu, C.; Duan, S.; et al. Defining the Sensitivity Landscape of EGFR Variants to Tyrosine Kinase Inhibitors. Transl. Res. 2022, in press. [Google Scholar] [CrossRef]
  108. Fowler, D.M.; Stephany, J.J.; Fields, S. Measuring the activity of protein variants on a large scale using deep mutational scanning. Nat. Protoc. 2014, 9, 2267–2284. [Google Scholar] [CrossRef]
  109. Glazer, A.M.; Kroncke, B.M.; Matreyek, K.A.; Yang, T.; Wada, Y.; Shields, T.; Salem, J.E.; Fowler, D.M.; Roden, D.M. Deep Mutational Scan of an SCN5A Voltage Sensor. Circ. Genom. Precis. Med. 2020, 13, e002786. [Google Scholar] [CrossRef]
  110. Heredia, J.D.; Park, J.; Brubaker, R.J.; Szymanski, S.K.; Gill, K.S.; Procko, E. Mapping Interaction Sites on Human Chemokine Receptors by Deep Mutational Scanning. J. Immunol. 2018, 200, 3825–3839. [Google Scholar] [CrossRef] [Green Version]
  111. Jones, E.M.; Lubock, N.B.; Venkatakrishnan, A.J.; Wang, J.; Tseng, A.M.; Paggi, J.M.; Latorraca, N.R.; Cancilla, D.; Satyadi, M.; Davis, J.E.; et al. Structural and functional characterization of G protein-coupled receptors with deep mutational scanning. eLife 2020, 9, e54895. [Google Scholar] [CrossRef]
  112. Coyote-Maestas, W.; Nedrud, D.; He, Y.; Schmidt, D. Determinants of trafficking, conduction, and disease within a K(+) channel revealed through multiparametric deep mutational scanning. eLife 2022, 11, e76903. [Google Scholar] [CrossRef] [PubMed]
Biology 12 00505 g001 550
Figure 1. Schematic diagram of Connexins. (A) Basic structure of Connexin 26; (B) Structure of connexons and (homotypic/heterotypic) gap junction channels. Homotypic gap junction channels are composed of two identical connexons. Heterotypic gap junction channels are composed of two different connexons.
Figure 1. Schematic diagram of Connexins. (A) Basic structure of Connexin 26; (B) Structure of connexons and (homotypic/heterotypic) gap junction channels. Homotypic gap junction channels are composed of two identical connexons. Heterotypic gap junction channels are composed of two different connexons.
Biology 12 00505 g001
Biology 12 00505 g002 550
Figure 2. Life cycle of Cx26. Green hemichannels represent Cx26; the hemichannels in other colors represent other connexins. Green gap junction channels represent homotypic gap junction channels composed of Cx26. Yellow gap junction channels represent homotypic gap junction channels composed of other connexins. The green and yellow gap junction channels are heterotypic or heteromeric or other types of junction channels composed of Cx26 and other connexins.
Figure 2. Life cycle of Cx26. Green hemichannels represent Cx26; the hemichannels in other colors represent other connexins. Green gap junction channels represent homotypic gap junction channels composed of Cx26. Yellow gap junction channels represent homotypic gap junction channels composed of other connexins. The green and yellow gap junction channels are heterotypic or heteromeric or other types of junction channels composed of Cx26 and other connexins.
Biology 12 00505 g002
Biology 12 00505 g003 550
Figure 3. Schematic diagram of the pathogenic mechanism of different phenotypes caused by GJB2 missense mutants. (A) In autosomal recessive nonsyndromic HL, most missense mutants are retained in the cell. A small fraction can traffic to the cell membrane, forming nonfunctional or functionally impaired hemichannels or functional homozygous GJ channels but not functional heterozygous channels. (B) In autosomal dominant nonsyndromic HL, most missense mutants are correctly trafficked to the cell membrane but form impaired GJ channels. (C) In autosomal dominant syndromic HL, some missense mutants can induce cell death due to increased calcium channel activity, resulting in increased hemichannel currents. (D) In autosomal dominant syndromic HL, most missense mutants have dominant-negative or trans-dominant effects on wildtype or other proteins, so the connexons coexpressed with the mutant are suppressed and form nonfunctional GJ channels. Green connexons represent the wildtype Cx26; yellow, orange, and blue connexons represent mutated Cx26; purple connexons represent other connexons.
Figure 3. Schematic diagram of the pathogenic mechanism of different phenotypes caused by GJB2 missense mutants. (A) In autosomal recessive nonsyndromic HL, most missense mutants are retained in the cell. A small fraction can traffic to the cell membrane, forming nonfunctional or functionally impaired hemichannels or functional homozygous GJ channels but not functional heterozygous channels. (B) In autosomal dominant nonsyndromic HL, most missense mutants are correctly trafficked to the cell membrane but form impaired GJ channels. (C) In autosomal dominant syndromic HL, some missense mutants can induce cell death due to increased calcium channel activity, resulting in increased hemichannel currents. (D) In autosomal dominant syndromic HL, most missense mutants have dominant-negative or trans-dominant effects on wildtype or other proteins, so the connexons coexpressed with the mutant are suppressed and form nonfunctional GJ channels. Green connexons represent the wildtype Cx26; yellow, orange, and blue connexons represent mutated Cx26; purple connexons represent other connexons.
Biology 12 00505 g003
Biology 12 00505 g004 550
Figure 4. The type (simple and complex) and pathogenicity classification of GJB2 missense variants.
Figure 4. The type (simple and complex) and pathogenicity classification of GJB2 missense variants.
Biology 12 00505 g004
Biology 12 00505 g005 550
Figure 5. Schematic diagram of deep mutational scanning on the GJB2 missense variants. First, a variant library containing 4294 missense variants will be constructed. Second, functional assays will be performed to evaluate the variants’ effects on connexin trafficking, hemichannel activity, GJC function, cell death, and coexpressed Cxs. Finally, a functional profile will be obtained based on the change in the frequency of the variants during the selection. Green connexons represent mutated Cx26; the yellow connexons represent wildtype Cx26 (dominant-negative effect assay) or other wildtype connexons (trans-dominant effect assay).
Figure 5. Schematic diagram of deep mutational scanning on the GJB2 missense variants. First, a variant library containing 4294 missense variants will be constructed. Second, functional assays will be performed to evaluate the variants’ effects on connexin trafficking, hemichannel activity, GJC function, cell death, and coexpressed Cxs. Finally, a functional profile will be obtained based on the change in the frequency of the variants during the selection. Green connexons represent mutated Cx26; the yellow connexons represent wildtype Cx26 (dominant-negative effect assay) or other wildtype connexons (trans-dominant effect assay).
Biology 12 00505 g005
Table
Table 2. Molecular mechanisms and phenotypes of syndromic hearing loss variants.
Table 2. Molecular mechanisms and phenotypes of syndromic hearing loss variants.
VariantsLocationsInheritance PatternsTraffickingHemichannelsGap Junction ChannelCell DeathDominant Negtive/Trans-Dominant EffectsClinical PhenotypeReferences
G11ENTADdefectIncreased/Increased/KID[83,84]
G12RNTADimpairedIncreasedimpairedIncreasedYES KID[29,85,86,87]
N14YNTADimpairedIncreasedimpaired//KID[86,88]
N14KNTADdefectIncreasedimpairedIncreased/KID[24,85]
S17FNTADimpaireddefectimpaired//KID[29,85,86]
I30NTM1ADimpairedIncreased///KID[89,90]
A40VTM1AD/IncreasedimpairedIncreased/KID[91,92]
G45EEC1ADimpairedIncreasedimpairedIncreasedYESKID[54,91]
D50AEC1ADimpairedIncreased/ KID[93]
D50NEC1ADdefectIncreasedimpairedIncreased/KID, HID[30,83,85]
D50YEC1ADimpairedIncreased///KID[89]
N54KEC1ADdefectimpairedimpaired/YESBPS, PPK + deafness[24,31,44]
G59AEC1ADdefect/impaired/YESPPK + deafness[52,53]
Y65HEC1ADimpaired/impaired//Vohwinkel[94]
D66HEC1ADdefectimpairedimpaired/YES/Vohwinkel[52,87]
H73REC1ADimpaired/impaired/YESPPK + deafness[95,96]
R75QTM2ADnormal/impaired/YESPPK + deafness[53]
R75WTM2ADnormal/impaired/YESPPK + deafness[52,53]
A88VTM2ADimpairedIncreased///KID[93]
F142LTM3ADimpairedimpairedimpaired/YES/Keratoderma-Deafness-Mucocutaneous Syndrome[87,97]
S183FTM4ADimpairedimpairedimpaired/YESPPK + deafness[24]
NT: N-term, TM: transmembrane, EC: extracellular loop, CL: cytoplasmic loop, AD: autosomal dominant, AR: autosomal recessive.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Mao, L.; Wang, Y.; An, L.; Zeng, B.; Wang, Y.; Frishman, D.; Liu, M.; Chen, Y.; Tang, W.; Xu, H. Molecular Mechanisms and Clinical Phenotypes of GJB2 Missense Variants. Biology 2023, 12, 505. https://doi.org/10.3390/biology12040505

AMA Style

Mao L, Wang Y, An L, Zeng B, Wang Y, Frishman D, Liu M, Chen Y, Tang W, Xu H. Molecular Mechanisms and Clinical Phenotypes of GJB2 Missense Variants. Biology. 2023; 12(4):505. https://doi.org/10.3390/biology12040505

Chicago/Turabian Style

Mao, Lu, Yueqiang Wang, Lei An, Beiping Zeng, Yanyan Wang, Dmitrij Frishman, Mengli Liu, Yanyu Chen, Wenxue Tang, and Hongen Xu. 2023. "Molecular Mechanisms and Clinical Phenotypes of GJB2 Missense Variants" Biology 12, no. 4: 505. https://doi.org/10.3390/biology12040505

APA Style

Mao, L., Wang, Y., An, L., Zeng, B., Wang, Y., Frishman, D., Liu, M., Chen, Y., Tang, W., & Xu, H. (2023). Molecular Mechanisms and Clinical Phenotypes of GJB2 Missense Variants. Biology, 12(4), 505. https://doi.org/10.3390/biology12040505

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop